Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase‐4 inhibitors: A population‐based cohort study using Japanese Latter‐Stage Elderly Healthcare Database
Journal of Diabetes Investigation · 2023
DOI: 10.1111/jdi.14004 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Diabetes Investigation, 2023. Verfasst von Yumi Harano und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Care Administration and Management, Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Fukuoka, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Pemphigoid, Bullous. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Aims/Introduction Although the association between dipeptidyl peptidase‐4 (DPP‐4) inhibitors and bullous pemphigoid (BP) has begun to be established, some studies have suggested there are risk differences among DPP‐4 inhibitors. We conducted a population‐based cohort study to examine the risk differences. Materials and Methods Using the claims databases of the Fukuoka Prefecture Wide‐Area Association of Latter‐Stage Elderly Healthcare between April 1, 2013 and March 31, 2017, we conducted a retrospective cohort study to compare patients receiving one DPP‐4 inhibitor with those who were prescribed another antidiabetic drug. The primary outcome was an adjusted hazard ratio (HR) of the development of bullous pemphigoid during a 3‐year follow‐up. The secondary outcome was the development of BP requiring systemic steroids immediately after the diagnosis. These were estimated using Cox proportional hazards regression models.
Results
The study comprised 33,241 patients, of which 0.26% ( n = 88) developed bullous pemphigoid during follow‐up. The percentages of patients with bullous pemphigoid who required immediate systemic steroid treatment was 0.11% ( n = 37). We analyzed four DPP‐4 inhibitors: sitagliptin, vildagliptin, alogliptin, and linagliptin. Vildagliptin and linagliptin raised the risk of BP significantly (primary outcome, vildagliptin, HR 2.411 [95% confidence interval (CI) 1.325–4.387], linagliptin, HR 2.550 [95% CI 1.266–5.136], secondary outcome, vildagliptin HR 3.616 [95% CI 1.495–8.745], linagliptin HR 3.556 [95% CI 1.262–10.024]). A statistically significant risk elevation was not observed with sitagliptin and alogliptin (primary outcome, sitagliptin, HR 0.911 [95% CI 0.508–1.635], alogliptin, HR 1.600 [95% CI 0.714–3.584], secondary outcome, sitagliptin, HR 1.192 [95% CI 0.475–2.992], alogliptin, HR 2.007 [95% CI 0.571–7.053]).
Conclusions
Not all the DPP‐4 inhibitors could induce bullous pemphigoid significantly. Therefore, the association warrants further investigations before generalization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Care Administration and Management, Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Fukuoka, Japan.
- Department of General Internal Medicine, Local Incorporated Administrative Agency Saga-Ken Medical Centre Koseikan, Saga, Japan.
- Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Fukuoka, Japan.
- Department of Health Sciences, Faculty of Medical Sciences, Kyushu University, Fukuoka City, Fukuoka, Japan.
ORCID-Profile: Yumi Harano
Zitieren
APA
Harano, Y., Mitamura, Y., Jiang, P., Fujita, T., & Babazono, A. (2023). Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase‐4 inhibitors: A population‐based cohort study using Japanese Latter‐Stage Elderly Healthcare Database. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.14004
Vancouver
Harano Y, Mitamura Y, Jiang P, Fujita T, Babazono A. Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase‐4 inhibitors: A population‐based cohort study using Japanese Latter‐Stage Elderly Healthcare Database. Journal of Diabetes Investigation. 2023. doi:10.1111/jdi.14004
BibTeX
@article{Harano2023,
author = {Harano, Yumi and Mitamura, Yasutaka and Jiang, Peng and Fujita, Takako and Babazono, Akira},
title = {Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase‐4 inhibitors: A population‐based cohort study using Japanese Latter‐Stage Elderly Healthcare Database},
journal = {Journal of Diabetes Investigation},
year = {2023},
doi = {10.1111/jdi.14004}
}
EUVIMED